The inhibition of anaplastic lymphoma kinase in non-small cell lung tumours with the ALK rearrangement may result in tumour shrinkage

Thorax

Volumn 66, Issue 4, 2011, Pages 332-

  Hancock, Louise ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER SCREENING; CANCER SURVIVAL; DRUG RESPONSE; ENZYME INHIBITION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; TREATMENT DURATION;

EID: 79953029155     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2011.159467     Document Type: Article

References (1)

1. Kwak EL, Bang Y, Camidge R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.